Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

Summary

The purpose of this study is to test the safety of escalating doses of the novel PI3K inhibitor WX-037 and to explore its effectiveness in combination with WX-554 which targets mitogen activated protein kinase (MEK1 and MEK2). Preclinical evidence indicates that these two novel compounds could provide targeted inhibition of both pathways to block tumour growth.

Timeline

Start

2013-07

Primary completion

2014-04

Completion

2014-04

Outcome

Outcome not reported

Stopped (Business): “Study terminated for business reasons”

Drugs

Indications